Physician profile
David Rubin
NPI 1003857616
$397,373.24
in general payments reported to CMS, 2019-2025
27 companies · $110K in 2025
The $110K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $22K · 2021: $15K · 2022: $45K · 2023: $75K · 2024: $58K · 2025: $110K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $194K · Travel and Lodging: $30K · Food and Beverage: $12K · Consulting Fee: $6,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $194,112.50 |
| Travel and Lodging | $29,735.85 |
| Food and Beverage | $12,373.45 |
| Consulting Fee | $6,825.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $310,649.91 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $78,584.65 | 2019-2025 | Biktarvy, Yeztugo, Descovy |
| Theratechnologies INC. | $3,228.06 | 2019-2025 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $1,315.99 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $960.97 | 2019-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Abbvie INC. | $677.10 | 2019-2025 | Vraylar |
| Pfizer INC. | $301.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $286.20 | 2019-2025 | Breztri, Farxiga |
| Janssen Products, LP | $254.92 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.57 | 2023-2025 | Xifaxan |
| Endo Pharmaceuticals INC. | $148.37 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.98 | 2019-2022 | |
| Antares Pharma, INC. | $123.38 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $78.82 | 2023-2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $66.81 | 2023-2024 | Wellbutrin, Aplenzin |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $66.01 | 2022-2023 | Serostim |
| Janssen Scientific Affairs, LLC | $58.09 | 2022-2023 | Symtuza |
| Idorsia Pharmaceuticals US INC | $42.50 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $37.88 | 2021-2022 | |
| Hologic Sales and Service, LLC | $33.84 | 2021 | |
| Boston Scientific Corporation | $33.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Halozyme INC | $24.88 | 2023 | |
| Lilly USA, LLC | $22.94 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.06 | 2025 | Nuzyra |
| Acerus Pharmaceuticals Corporation | $17.99 | 2022 | |
| Echosens North America, INC. | $13.66 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.